STEADY-STATE PLASMA-CONCENTRATIONS OF MIANSERIN AND ITS MAJOR ACTIVE METABOLITE, DESMETHYLMIANSERIN

被引:20
作者
OTANI, K
SASA, H
KANEKO, S
KONDO, T
FUKUSHIMA, Y
机构
[1] Department of Neuropsychiatry, Hirosaki University Hospital, Hirosaki
关键词
MIANSERIN; DESMETHYLMIANSERIN; PLASMA CONCENTRATION; STEADY STATE;
D O I
10.1097/00007691-199304000-00008
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The steady-state plasma concentrations of mianserin and its major active metabolite, desmethylmianserin, were measured in 76 depressed patients receiving 30 mg of mianserin at bedtime. There were considerable inter-individual variations in the steady-state plasma concentrations of these compounds; the plasma concentrations of mianserin plus desmethylmianserin were within the therapeutic range suggested previously by us in only 43% of the patients. With advancing age, the plasma concentrations of mianserin increased significantly, while those of mianserin plus desmethylmianserin remained unchanged. Sex, smoking, and coadministration of benzodiazepines did not affect the drug's metabolism. There was no evidence that the kinetics of these compounds were nonlinear with increasing doses. The present study thus suggests that measuring the plasma concentrations of mianserin and desmethylmianserin contributes to rational treatment with this drug, that age, sex, smoking, and coadministration of benzodiazepines are not important factors in determining the dose, and that these compounds have linear kinetics.
引用
收藏
页码:113 / 117
页数:5
相关论文
共 25 条
[1]  
ABERNETHY DR, 1985, J PHARMACOL EXP THER, V232, P183
[2]   IMPORTANCE OF OXIDATIVE POLYMORPHISM AND LEVOMEPROMAZINE TREATMENT ON THE STEADY-STATE BLOOD-CONCENTRATIONS OF CLOMIPRAMINE AND ITS MAJOR METABOLITES [J].
BALANTGORGIA, AE ;
BALANT, LP ;
GENET, C ;
DAYER, P ;
AESCHLIMANN, JM ;
GARRONE, G .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 31 (04) :449-455
[3]   VARIABILITY IN THE ELIMINATION OF MIANSERIN IN ELDERLY PATIENTS [J].
BEGG, EJ ;
SHARMAN, JR ;
KIDD, JE ;
SAINSBURY, R ;
CLARK, DWJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 27 (04) :445-451
[4]   THE DEBRISOQUINE HYDROXYLATION TEST PREDICTS STEADY-STATE PLASMA-LEVELS OF DESIPRAMINE [J].
BERTILSSON, L ;
ABERGWISTEDT, A .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 15 (03) :388-390
[5]   ALPRAZOLAM DOES NOT INHIBIT THE METABOLISM OF NORTRIPTYLINE IN DEPRESSED-PATIENTS OR INHIBIT THE METABOLISM OF DESIPRAMINE IN HUMAN-LIVER MICROSOMES [J].
BERTILSSON, L ;
ABERGWISTEDT, A ;
LIDEN, A ;
OTANI, K ;
SPINA, E .
THERAPEUTIC DRUG MONITORING, 1988, 10 (02) :231-233
[6]   STEADY-STATE CONCENTRATIONS OF IMIPRAMINE AND ITS METABOLITES IN RELATION TO THE SPARTEINE DEBRISOQUINE POLYMORPHISM [J].
BROSEN, K ;
KLYSNER, R ;
GRAM, LF ;
OTTON, SV ;
BECH, P ;
BERTILSSON, L .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 30 (06) :679-684
[7]   FATAL TOXICITY OF ANTIDEPRESSANT DRUGS IN OVERDOSE [J].
CASSIDY, S ;
HENRY, J .
BRITISH MEDICAL JOURNAL, 1987, 295 (6605) :1021-1024
[8]   MIANSERIN AND AGRANULOCYTOSIS IN NEW-ZEALAND [J].
COULTER, DM ;
EDWARDS, IR .
LANCET, 1990, 336 (8718) :785-787
[9]   TOBACCO SMOKING AND DRUGS - A CLINICALLY IMPORTANT INTERACTION [J].
DARCY, PF .
DRUG INTELLIGENCE & CLINICAL PHARMACY, 1984, 18 (04) :302-307
[10]  
INMAN WHW, 1988, LANCET, V2, P90